M.D. Anderson Cancer Center
To find the recommended dose of vorasidenib that can be given to participants with IDH2-mutated iCCA.
Primary Objectives and Endpoints To evaluate the safety and efficacy of vorasidenib in participants with IDH2-mutated iCCA. Primary endpoints for the study will be the evaluation of dose-limiting toxicities (DLTs) and landmark progression-free survival (PFS).
Eligibility Criteria 1. Patients with diagnosis of unresectable or metastatic iCCA (confirmed by treating clinician) who have received at least one first-line standard of care systemic therapy for iCCA. 2. Patients must have received a standard first-line therapy (as per NCCN guidelines) for cholangiocarcinoma/ biliary cancer 3. Presence of an IDH2 mutation confirmed by laboratory testing using validated methods, such as polymerase chain reaction (PCR) or next-generation sequencing (NGS). 4. Patients must have measurable disease, defined as at least one lesion that can be accurately measured…
Give by po
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.